Chemical Constitution, Pharmacological Effects and the Underlying Mechanism of Atractylenolides: A Review
Affiliations
Atractylenolides, comprising atractylenolide I, II, and III, represent the principal bioactive constituents of , a traditional Chinese medicine. These compounds exhibit a diverse array of pharmacological properties, including anti-inflammatory, anti-cancer, and organ-protective effects, underscoring their potential for future research and development. Recent investigations have demonstrated that the anti-cancer activity of the three atractylenolides can be attributed to their influence on the JAK2/STAT3 signaling pathway. Additionally, the TLR4/NF-κB, PI3K/Akt, and MAPK signaling pathways primarily mediate the anti-inflammatory effects of these compounds. Atractylenolides can protect multiple organs by modulating oxidative stress, attenuating the inflammatory response, activating anti-apoptotic signaling pathways, and inhibiting cell apoptosis. These protective effects extend to the heart, liver, lung, kidney, stomach, intestine, and nervous system. Consequently, atractylenolides may emerge as clinically relevant multi-organ protective agents in the future. Notably, the pharmacological activities of the three atractylenolides differ. Atractylenolide I and III demonstrate potent anti-inflammatory and organ-protective properties, whereas the effects of atractylenolide II are infrequently reported. This review systematically examines the literature on atractylenolides published in recent years, with a primary emphasis on their pharmacological properties, in order to inform future development and application efforts.
Jianan Y, Kunming C, Chao L, Xiang Z, Zeyu D, Bing L J Tradit Chin Med. 2025; 45(1):57-65.
PMID: 39957159 PMC: 11764933. DOI: 10.19852/j.cnki.jtcm.2025.01.006.
Atractylenolide I prevents acute liver failure in mouse by regulating M1 macrophage polarization.
Zhang H, Gao M, Wang H, Zhang J, Wang L, Dong G Sci Rep. 2025; 15(1):4015.
PMID: 39893238 PMC: 11787394. DOI: 10.1038/s41598-025-86977-x.
Li S, Wang B, Deng J, Li H, Wu Y, Fang Y J Pain Res. 2025; 18:33-42.
PMID: 39802415 PMC: 11721491. DOI: 10.2147/JPR.S500305.
Zeng C, Liu F, Huang Y, Liang Q, He X, Li L Int J Mol Sci. 2024; 25(23).
PMID: 39684456 PMC: 11641265. DOI: 10.3390/ijms252312742.
Wen X, Xiao Z Neuropsychiatr Dis Treat. 2024; 20:2057-2058.
PMID: 39494381 PMC: 11531294. DOI: 10.2147/NDT.S500373.